The Role of Immunotherapy in Infectious Disease Treatment

Morales Antonio^*
*Correspondence: Morales Antonio, Department of Epidemiology, University of Singapore, Lower Kent Ridge Rd, Singapore, Email:

Introduction

Immunotherapy has emerged as a promising approach in the treatment of infectious diseases, leveraging the body's own immune system to fight pathogens more effectively. Unlike conventional antibiotics or antiviral medications, which directly target the pathogens, immunotherapy enhances the immune response, helping the body to recognize, attack and eliminate infections more efficiently [1]. One of the most well-known applications of immunotherapy in infectious disease treatment is the use of monoclonal antibodies. These laboratory-engineered antibodies mimic the body's natural immune response and are designed to target specific antigens present on infectious agents. For instance, monoclonal antibodies such as REGN-COV2 were developed to combat COVID-19, reducing the severity and duration of the disease in infected individuals [2]. Similar strategies have been applied in the treatment of Ebola, where monoclonal antibody therapies like Inmazeb and Ebanga have shown significant success in improving survival rates.

Description

Another critical aspect of immunotherapy is the development of therapeutic vaccines. Unlike prophylactic vaccines, which aim to prevent infections, therapeutic vaccines are designed to boost the immune system's response to an existing infection. A prominent example is the therapeutic vaccine research for chronic infections such as HIV and hepatitis B. These vaccines work by stimulating the immune system to mount a stronger attack against the virus, potentially leading to viral suppression or even eradication [3,4]. Cytokine therapy is another innovative approach within immunotherapy. Cytokines are signaling proteins that modulate immune responses and their administration can enhance the body's ability to combat infections. For instance, interferon therapy has been used to treat chronic viral infections like hepatitis C, helping the immune system to recognize and clear infected cells more effectively.

Adoptive cell therapy, including T-cell therapy, is also being explored for infectious diseases. This involves the extraction, modification and reinfusion of immune cells to enhance their ability to target specific pathogens. Research in this area has gained traction in addressing latent infections such as cytomegalovirus and Epstein-Barr virus (EBV), particularly in immunocompromised patients [5]. Advancements in precision medicine and biomarker research are expected to refine immunotherapy approaches, making them safer and more effective. The role of immunotherapy is also expanding in the fight against antimicrobial resistance. With the increasing ineffectiveness of antibiotics due to resistant bacterial strains, immunotherapies such as bacteriophage therapy and immune checkpoint inhibitors offer alternative solutions by either using viruses to target bacteria or enhancing the immune systemâ??s ability to eliminate resistant pathogens.

Conclusion

Despite its promise, immunotherapy in infectious disease treatment comes with challenges. High costs, the complexity of immune system interactions and potential side effects, such as cytokine storms, require careful consideration. However, continued advancements in immunology, biotechnology and personalized medicine are likely to overcome these hurdles, making immunotherapy a crucial component in the future of infectious disease management. Personalized immunotherapy represents a revolutionary shift in infectious disease treatment, offering targeted, long-lasting and effective solutions where conventional treatments fall short. With ongoing research and technological advancements, immunotherapy is poised to play an increasingly vital role in combating infectious diseases worldwide.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Adegunsoye, Ayodeji and Jay Balachandran. “Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea.” Mediat Inflamm (2015).

Google Scholar      Cross Ref    Indexed at

2. Lai, Meng-Jiun, Chih-Chin Liu, Shinn-Jong Jiang and Po-Chi Soo, et al. “Antimycobacterial activities of endolysins derived from a mycobacteriophage, BTCU-1.” Molecules20 (2015): 19277-19290.

Google Scholar      Cross Ref    Indexed at

3. Walton, Clare, Rachel King, Lindsay Rechtman and Wendy Kaye, et al. “Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS.” Mult Scler 26 (2020): 1816-1821.

Google Scholar      Cross Ref    Indexed at

4. De Groot, C. J. A., E. Bergers, W. Kamphorst and R. Ravid, et al. “Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p) reactive lesions.” Brain124 (2001): 1635-1645. 

Google Scholar      Cross Ref    Indexed at

5. Catassi, Carlo, Simona Gatti and Elena Lionetti. “World perspective and celiac disease epidemiology.” Dig Dis33 (2015): 141-146.

Google Scholar      Cross Ref    Indexed at